Why Is ASPI Stock Extending Gains Overnight Today?

• Radiopharmaceutical businesses accounted for the largest share of revenue, at about $3.4 million.
• Both Q1 revenue and EPS beat Street estimates. 
• ASP Isotopes expects initial deliveries of enriched silicon-28 products around mid-2026.

ASP Isotopes (ASPI) stock gained over 1% overnight on Wednesday, following a more than 8% surge in the regular session, after the company released its fiscal first-quarter earnings and outlined plans to expand isotope production for quantum computing, nuclear medicine and advanced energy markets. 

ASPI’s Q1 Financial Performance 

The company reported Q1 revenue of $4.18 million, a 278% year-on-year jump and a $0.06 loss per share. Both metrics exceeded analysts’ consensus estimates of $3.68 million and a $0.28 loss per share, respectively, according to Fiscal AI data. 

Radiopharmaceutical operations contributed the largest share of revenue at about $3.4 million, while LNG operations linked with Renergen added about $600,000. 

However, the company reported a surge in operating expenses to $26.5 million, up from $8.3 million last year. ASP Isotopes ended the quarter with more than $207 million in cash and cash equivalents. 

ASP Isotopes’ stock was up 1% overnight, after ending the regular trading session 8% higher. 

ASPI’s 2026 Commercial Pipeline

The Dallas-based company expects initial deliveries of enriched silicon-28 products around mid-2026. The enriched material is used in semiconductor and quantum computing applications because it helps reduce signal interference in advanced chips.

Commercial shipments of ytterbium-176 and carbon-14 are projected for the third quarter. Ytterbium-176 plays an important role in producing Lutetium-177 therapies used in targeted cancer treatment, while Carbon-14 supports pharmaceutical research.

ASP Isotopes said its helium production business for electronic materials is expected to reach full Phase 1 production capacity in the third quarter. The company also plans to expand its radiopharmacy operations and advance several radiopharmaceutical products into early-phase human clinical trials. 

The company also advanced plans for its Quantum Leap Energy subsidiary, which focuses on high-assay low-enriched uranium (HALEU) used in next-generation nuclear reactors. 

ASP Isotopes said the unit finalized supply agreements tied to TerraPower, the nuclear company backed by Bill Gates. In the long term, the company said it is targeting annual EBITDA above $300 million by 2031.

What Are ASPI Retail Traders Saying

On Stocktwits, retail sentiment around the stock jumped to ‘bullish’ from ‘neutral’ territory the previous day. Message volume increased 51% in 24 hours. 

A user said, “Nice bump on pet labs/radiopharma revenue.”

Another user said, “Carbon shipments Q3 2026.......,” highlighting the company’s nuclear medicine. 

ASPI stock has declined by nearly 2% year-to-date. 

Also See: Anthropic Is On Track For Its First Quarterly Profit: Report

For updates and corrections, email newsroom[at]stocktwits[dot]com.